14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
IMMX vs ATYR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Immix Biopharma, Inc. (IMMX) on higher Unified Composite conviction (34.3/100 SELL vs. 53.1/100 HOLD) after splitting the core matrix 1–4 (led by Options & Positioning), while IMMX wins 3–1 across the 6-pillar growth and valuation breakdown. IMMX trades at $7.20 (N/M Forward P/E, 0.0% operating margin) versus ATYR at $4.96 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While IMMX currently prints a higher short-term Unified Composite Score (53.1/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs ATYR. Trailing 12-month operating profitability (IMMX 0.0% vs ATYR 0.0%) and valuation multiples (IMMX N/M vs ATYR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IMMX vs ATYR Key Questions & Quantitative Answers
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Immix Biopharma, Inc. (IMMX) on higher Unified Composite conviction (34.3/100 SELL vs. 53.1/100 HOLD) after splitting the core matrix 1–4 (led by Options & Positioning), while IMMX wins 3–1 across the 6-pillar growth and valuation breakdown. IMMX trades at $7.20 (N/M Forward P/E, 0.0% operating margin) versus ATYR at $4.96 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While IMMX currently prints a higher short-term Unified Composite Score (53.1/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: IMMX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.7); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IMMX leads the Growth & Scale pillar: IMMX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IMMX generates N/A in USD-normalized revenue versus N/A for ATYR. In operating R&D and SG&A reinvestment, IMMX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.
IMMX and ATYR trade at balanced relative valuation multiples. IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMMX (-27.0% ROE) versus ATYR (-93.7% ROE) capital efficiency.
In options market volatility and institutional positioning, IMMX carries 92.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.83β · 83% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.